quinazolines has been researched along with Carcinoma, Renal Cell in 64 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (53.13) | 29.6817 |
| 2010's | 27 (42.19) | 24.3611 |
| 2020's | 2 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Chhabra, A; Eisen, T; Fife, K; Gallagher, FA; Matakidou, A; Mitchell, TJ; Mossop, H; Oades, G; Ortuzar, MC; Protheroe, A; Sala, E; Sipple, JAN; Skells, R; Stewart, GD; Stone, J; Sullivan, M; Thomas, MG; Ursprung, S; Venugopal, B; Walker, A; Warren, AY; Wason, J; Welsh, SJ; Young, G | 1 |
| Cochin, V; Godbert, Y; Gross-Goupil, M; Le Moulec, S; Ravaud, A | 1 |
| Cheng, S; Du, YM; Hou, XD; Liu, XM; Yuan, XL; Zhang, P; Zhang, ZF | 1 |
| Ackerman, C; Bahl, A; Beltran, L; Boleti, E; Brown, J; Chowdhury, S; Crabb, SJ; Dunlop, J; Fife, K; Geldart, T; Hall, PE; Hawkins, R; Hill, R; Jones, R; Larkin, J; McLaren, D; Nathan, P; Powles, T; Ralph, C; Shepherd, STC; Webb, A; Wimalasingham, A | 1 |
| Brown, C; De Souza, P; Fox, P; Gebski, V; Hudson, M; Lee, CK; Lord, S | 1 |
| Bedard, PL; Castonguay, V; Chen, EX; Chen, H; Chen, Z; Clarke, B; Cohen, B; Hirte, HW; Hotte, SJ; Ivy, SP; Kamel-Reid, S; Liu, G; McGarrity, A; Oza, AM; Razak, AR; Reedijk, M; Sahebjam, S; Siu, LL; Wang, L; Zhang, T; Zhang, WJ | 1 |
| Goh, V; Gore, M; Juttla, JK; Larkin, JM; Nathan, PD; Reynolds, AR; Thompson, VL; Vasudev, NS | 1 |
| Amantini, C; Berardi, R; Burattini, L; Cascinu, S; Conti, A; Muzzonigro, G; Santoni, G; Santoni, M | 1 |
| Chae, IG; Chun, KS; Kwon, TK; Min, KJ; Woo, SM | 1 |
| Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY | 1 |
| Chen, L; Li, Q; Liu, XD; Wu, B; Xu, HF; Zhan, YH; Zhang, HH | 1 |
| Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Khambati, HK; Knox, JJ; Kollmannsberger, CK; MacKenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wood, L | 1 |
| Ackerman, C; Beltran, L; Bhal, A; Boleti, E; Brown, J; Chowdhury, S; Crabb, S; Dunlop, J; Fife, K; Geldart, T; Hall, PE; Hawkins, R; Hill, R; Jones, R; Larkin, J; McLaren, D; Nathan, P; Powles, T; Ralph, C; Webb, A | 1 |
| Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S | 1 |
| Chen, YC; Chien, CC; Chiu, WT; Wu, WS | 1 |
| Bukowski, RM; Vakkalanka, BK | 1 |
| Fu, H; Hawk, N; Kauh, J; Khuri, FR; Ramalingam, SS; Sun, SY; Wang, X; Yue, P | 1 |
| Brazelle, WD; Jürgensmeier, JM; Siemann, DW | 1 |
| Choueiri, TK; Chowdhury, S | 1 |
| Asano, T; Hayakawa, M; Horiguchi, A; Ito, K; Kuroda, K; Sumitomo, M | 1 |
| Aparicio, A; Arap, W; Araujo, JC; Corn, PG; Jonasch, E; Matin, SF; Millikan, RE; Pagliaro, LC; Tamboli, P; Tannir, N; Tu, SM; Wang, X; Wood, CG | 1 |
| Clark, JI; Crawford, D; Dutcher, J; Gordon, MS; Hussey, M; Lara, PN; Mack, PC; Nagle, RB; Pan, CX; Quinn, DI; Samlowski, W | 1 |
| Yano, S | 1 |
| Drevs, J; Esser, N; Jürgensmeier, JM; Medinger, M; Ryan, A; Zirrgiebel, U | 1 |
| Cohen, MH; Keegan, P; Pazdur, R; Summers, J | 1 |
| Baum, MS; Chen, I; Ginsberg, MS; Harmon, CS; Hudes, GR; Kim, ST; Motzer, RJ; Redman, BG | 1 |
| Kats-Ugurlu, G; Kiemeney, LA; Leenders, WP; Mulders, PF; Old, LJ; Oosterwijk, E; Oosterwijk-Wakka, JC | 1 |
| Chua, BT; Lim, SJ; Poh, WJ; Tham, SC; Ullrich, A | 1 |
| Berros, JP; Blay, P; Corral, N; Esteban, E; Estrada, E; Fernández, Y; Fonseca, PJ; Fra, J; Izquierdo, M; Lacave, ÁJ; Luque, M; Muriel, C; Pardo, P; Sanmamed, M; Vieitez, JM; Villanueva, N | 1 |
| Bukowski, RM; Cooney, MM; Dreicer, R; Elson, P; Garcia, JA; Rini, BI; Shepard, DR | 1 |
| Breaker, K; Costa, LJ; Crighton, F; Drabkin, H; Flaig, TW; Gustafson, DL; Kim, FJ; Schultz, MK | 1 |
| Frankel, P; Gandara, DR; Lara, PN; Longmate, J; Margolin, KA; Pan, CX; Quinn, DI; Shek, D; Twardowski, P | 1 |
| Bai, L; Evans, CP; Kung, HJ; Mack, PC; Ok, JH; Yang, JC | 1 |
| de Jong, I; Gore, ME; Hawkins, R; Jürgensmeier, JM; Mookerjee, B; Mulders, P; Nathan, P; Osanto, S; Pike, L; Porfiri, E; Protheroe, A; van Herpen, CM | 1 |
| Caparelli, F; Hoff, PM; Sahade, M | 1 |
| Bernhard, JC; Gross-Goupil, M; Ravaud, A | 1 |
| Andreu, X; Baena, C; Bronchud, MH; Castillo, S; Escriva de Romaní, S; Esquius, J; Fernández, A; Julia, JC; Mourelo, S; Murillo, J; Romero, R | 1 |
| Chen, EX; Haider, MA; Halford, R; Hotte, SJ; Ivy, SP; Kollmannsberger, C; Mackenzie, MJ; Moore, MJ; Mukherjee, SD; Murray, N; Sridhar, SS; Tannock, IF; Wang, L | 1 |
| Fleck, C; Hilger, R; Jurkutat, S; Karge, E; Merkel, U; Schimske, A; Schubert, J | 1 |
| Bacik, J; Drucker, B; Ginsberg, M; Marion, S; Mazumdar, M; Motzer, R; Russo, P | 1 |
| Asakuma, J; Asano, T; Hayakawa, M; Sumitomo, M | 1 |
| Asakuma, J; Asano, T; Hayakawa, M; Horiguchi, A; Sumitomo, M | 1 |
| Shi, W; Siemann, DW | 1 |
| Dawson, NA; Dorsey, B; Guo, C; Hussain, A; Smoot, J; Wong, J; Zak, R | 1 |
| Drevs, J; Esser, N; Konerding, MA; Ogilvie, DJ; Ryan, AJ; Wedge, SR; Wolloscheck, T | 1 |
| Bukowski, RM; Costa, L; Drabkin, HA; Gemmill, RM; Korch, C; Zhou, M | 1 |
| Bauer, JA; Cerny, T; Egli, F; Gillessen, S; Jermann, M; Joerger, M; Morant, R; Pless, M; Rhyner, K; Salzberg, M; Stahel, RA | 1 |
| Cooney, MM; Remick, SC; Vogelzang, NJ | 1 |
| Hong, SJ; Jae, YW; Kim, SI; Kwon, SM; Oh, HY | 1 |
| Baughman, C; Edwards, DL; Greco, A; Hainsworth, JD; Sosman, JA; Spigel, DR | 1 |
| Lindsey, H | 1 |
| Hampton, T | 1 |
| Mancuso, A; Sternberg, CN | 1 |
| Bankhead, C | 1 |
| An, J; Rettig, MB | 1 |
| Costa, LJ; Drabkin, HA; Gemmill, RM | 1 |
| Bukowski, RM; Drabkin, HA; Dutcher, J; Figlin, RA; Flaherty, K; Kabbinavar, FF; McDermott, D; Ryba, S; Scappaticci, FA; Srinivas, S; Vaishampayan, U; Xia, Q | 1 |
| Dietrich, PY; Lübbe, J; Masouyé, I | 1 |
| Burris, HA; Cucullu, H; Farley, C; Greco, FA; Hainsworth, JD; Hart, LL; Sosman, JA; Spigel, DR; Sylvester, L; Waterhouse, DM; Yost, K | 1 |
| Amato, RJ; Hernandez-McClain, J; Jac, J | 1 |
| Audhuy, B; El-Hariry, I; Gardner, JP; Gore, M; Harper, P; Hawkins, R; Machiels, JP; Pétavy, F; Ravaud, A; Rolland, F; Schöffski, P; von der Maase, H; Zantl, N | 1 |
| Beekman, KE; Clark, JI; Davis, NB; Hussain, M; Lee, RT; Nichols, KF; Stadler, WM; Thomas, SP | 1 |
| Boselli, B; Bosl, G; Dershaw, D; Houston, C; Rosado, K; Rosenbluth, R; Scher, H; Sternberg, CN; Vinciguerra, V; Yagoda, A | 1 |
9 review(s) available for quinazolines and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Progress of molecular targeted therapies for advanced renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Phenylurea Compounds; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A | 2013 |
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Novel drugs for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2008 |
Recent advances in the systemic treatment of metastatic papillary renal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Papillary; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2009 |
[Molecular-targeted therapy in the developing stage. 1) VEGFR-TKI and EGFR-TKI].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; ErbB Receptors; Gefitinib; Humans; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2009 |
Cediranib: a VEGF receptor tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Glioblastoma; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Sarcoma | 2012 |
Lapatinib and renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Epidermal Growth Factor; ErbB Receptors; Humans; Kidney Neoplasms; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2012 |
Promising systemic therapy for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Administration Schedule; Epothilones; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2005 |
New treatment approaches in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2006 |
21 trial(s) available for quinazolines and Carcinoma, Renal Cell
| Article | Year |
|---|---|
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Biopsy; Capillary Permeability; Carcinoma, Renal Cell; Humans; Kidney; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Magnetic Resonance Imaging; Medical Futility; Nephrectomy; Non-Randomized Controlled Trials as Topic; Phthalazines; Piperazines; Proof of Concept Study; Quinazolines; Treatment Outcome; Tumor Burden | 2021 |
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.
Topics: Benzodioxoles; Carcinoma, Renal Cell; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Kidney Neoplasms; Male; Prognosis; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2020 |
Markers of systemic inflammation predict survival in patients with advanced renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Inflammation; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Leukocyte Count; Male; Megestrol Acetate; Middle Aged; Platelet Count; Prognosis; Quinazolines; Serum Albumin; Tamoxifen; Young Adult | 2013 |
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Renal Cell; Colorectal Neoplasms; Female; Humans; Kidney Neoplasms; Leiomyosarcoma; Male; Middle Aged; Neoplasms; Quinazolines; Sarcoma, Endometrial Stromal; Thyroid Neoplasms; Treatment Outcome; Uterine Neoplasms; Young Adult | 2013 |
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).
Topics: Aged; Benzodioxoles; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Quinazolines; Vascular Endothelial Growth Factor A | 2016 |
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Proportional Hazards Models; Prospective Studies; Quinazolines; Risk Assessment; Time Factors; Treatment Outcome; Wound Healing | 2009 |
Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Rate; Von Hippel-Lindau Tumor Suppressor Protein | 2009 |
Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrroles; Quinazolines; Sunitinib; Survival Analysis; Treatment Outcome | 2010 |
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Ohio; Piperazines; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Time Factors; Treatment Outcome | 2012 |
A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Female; Gefitinib; Humans; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Quinazolines; Recombinant Proteins | 2011 |
Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.
Topics: Aged; Algorithms; Antineoplastic Agents; Carcinoma, Renal Cell; Double-Blind Method; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Placebos; Quinazolines; Treatment Outcome; Tumor Burden | 2012 |
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Contrast Media; Demography; Disease Progression; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Gefitinib; Humans; Kidney Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate; Treatment Outcome | 2003 |
A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Outcome | 2004 |
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; ErbB Receptors; Female; Gefitinib; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Recurrence; Tomography, X-Ray Computed | 2006 |
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
Topics: Adenocarcinoma, Clear Cell; Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2005 |
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Placebos; Quinazolines; Treatment Outcome | 2007 |
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bevacizumab; Carcinoma, Renal Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imatinib Mesylate; Kidney Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor | 2007 |
Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Imatinib Mesylate; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Survival Rate | 2008 |
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Carcinoma, Renal Cell; Disease-Free Survival; ErbB Receptors; Female; Humans; Immunohistochemistry; Kidney Neoplasms; Lapatinib; Male; Megestrol Acetate; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Tamoxifen | 2008 |
A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer.
Topics: Aged; Aged, 80 and over; Benzamides; Carcinoma, Papillary; Carcinoma, Renal Cell; Chicago; Dose-Response Relationship, Drug; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Safety; Universities | 2008 |
34 other study(ies) available for quinazolines and Carcinoma, Renal Cell
| Article | Year |
|---|---|
[Cabozantinib: Mechanism of action, efficacy and indications].
Topics: Anilides; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Piperidines; Prostatic Neoplasms; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Cytological Assessments and Transcriptome Profiling Demonstrate that Evodiamine Inhibits Growth and Induces Apoptosis in a Renal Carcinoma Cell Line.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Quinazolines; Signal Transduction; Transcriptome | 2017 |
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Vessels; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides; Sunitinib | 2013 |
Silymarin suppresses the PGE2 -induced cell migration through inhibition of EP2 activation; G protein-dependent PKA-CREB and G protein-independent Src-STAT3 signal pathways.
Topics: Alprostadil; Antioxidants; Benzodioxoles; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Dinoprostone; Down-Regulation; Enzyme Activation; Enzyme Inhibitors; GTP-Binding Proteins; HCT116 Cells; HT29 Cells; Humans; Integrases; Kidney Neoplasms; Phosphorylation; Prostaglandin Antagonists; Quinazolines; Receptors, Prostaglandin E, EP2 Subtype; RNA Interference; RNA, Small Interfering; Signal Transduction; Silymarin; src-Family Kinases; STAT3 Transcription Factor; Wound Healing; Xanthones | 2015 |
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins | 2013 |
Targeting EGFL7 expression through RNA interference suppresses renal cell carcinoma growth by inhibiting angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Calcium-Binding Proteins; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; EGF Family of Proteins; Endothelial Growth Factors; ErbB Receptors; Female; Focal Adhesion Protein-Tyrosine Kinases; Gefitinib; Humans; Kidney Neoplasms; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2014 |
Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Protein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma Cells.
Topics: Adenine; Animals; Anthracenes; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; eIF-2 Kinase; Gene Expression Regulation; Humans; Indoles; JNK Mitogen-Activated Protein Kinases; Kidney Neoplasms; Male; Membrane Potential, Mitochondrial; Mice, Nude; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Kidney Neoplasms; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2008 |
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Endothelial Cells; Endothelium, Vascular; Humans; Kidney Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2009 |
Activated Akt prevents antitumor activity of gefitinib in renal cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Gefitinib; Humans; Kidney Neoplasms; Oncogene Protein v-akt; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2009 |
Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Disease Models, Animal; Female; Immunoenzyme Techniques; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2009 |
FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endpoint Determination; Erlotinib Hydrochloride; Female; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recombinant Proteins; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2010 |
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrases; Carcinoma, Renal Cell; Drug Synergism; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2011 |
Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Kidney Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Ubiquitin | 2010 |
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chromatography, Liquid; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Tandem Mass Spectrometry | 2010 |
Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Topics: Benzodioxoles; Carcinoma, Renal Cell; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; src-Family Kinases; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
HER2 blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Humans; Injections, Intravenous; Kidney Neoplasms; Lapatinib; Male; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Carcinoma, Renal Cell; Cisplatin; Dexamethasone; Epidermal Growth Factor; Female; Glucocorticoids; Humans; Kidney; Kidney Neoplasms; Methotrexate; Quinazolines; Rats; Rats, Wistar; Thiophenes; Topotecan; Triiodothyronine | 2002 |
Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Division; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Quinazolines | 2004 |
ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Down-Regulation; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Kidney Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Paclitaxel; Phosphorylation; Quinazolines; Time Factors | 2004 |
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Humans; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Organophosphorus Compounds; Piperidines; Quinazolines; Sarcoma, Kaposi | 2004 |
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.
Topics: Animals; Blood Vessels; Carcinoma, Renal Cell; Cell Division; Enzyme Inhibitors; Humans; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Quinazolines | 2004 |
Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Kidney Neoplasms; Mutation; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Von Hippel-Lindau Tumor Suppressor Protein | 2005 |
Antiangiogenic effect of ZD1839 against murine renal cell carcinoma (RENCA) in an orthotopic mouse model.
Topics: Animals; Biopsy, Needle; Blotting, Western; Carcinoma, Renal Cell; Cell Proliferation; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Quinazolines; Sensitivity and Specificity; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Bevacizumab and erlotinib show promise for kidney cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
Trials probe new agents for kidney cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Lapatinib; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2006 |
Three new drugs available to fight kidney cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Lapatinib; Multicenter Studies as Topic; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
New hope for RCC patients.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lapatinib; Pyrroles; Quinazolines; Sirolimus; Sunitinib | 2006 |
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Cycle; Cell Death; Cell Survival; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Inhibitory Concentration 50; Kidney Neoplasms; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines | 2007 |
Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells.
Topics: Antibiotics, Antineoplastic; Benzamides; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Renal Cell; Cell Cycle; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Kidney Neoplasms; Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2007 |
Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva).
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dermatitis; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kidney Neoplasms; Middle Aged; Neutrophils; Protein Kinase Inhibitors; Quinazolines; Skin | 2008 |
Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Evaluation; Folic Acid Antagonists; Humans; Kidney Neoplasms; Middle Aged; Quinazolines; Trimetrexate | 1989 |